STCube

STCube Net Margin

The Net Profit Margin of STCube (052020.KQ) as of Oct 24, 2026 is -312.14 %. In the previous year, Net Profit Margin was -189.74 % — a change of 64.50% (lower).

Net Margin

-312.14 %

YoY

64.50%

Last updated:

Net Profit Margin of STCube is 2025 -312.14 % . Net Profit Margin of STCube was 2024 -189.74 % . It decreases by 64.50% lower compared to the previous year.

STCube's net margin stands at -312.1%, down from -271.6% several years earlier.

The STCube Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2018
-102.26 KRW
Jan 1, 2019
-69.28 KRW
Jan 1, 2020
-157.58 KRW
Jan 1, 2021
-271.64 KRW
Jan 1, 2022
-299.76 KRW
Jan 1, 2023
-420.43 KRW
Jan 1, 2024
-189.74 KRW
Jan 1, 2025
-312.14 KRW
The STCube Net Margin history
YEARNet MarginYoY
-312.14 %+64.50%
-189.74 %-54.87%
-420.43 %+40.26%
-299.76 %+10.35%
-271.64 %+72.37%
-157.58 %+127.45%
-69.28 %-32.25%
-102.26 %-47.42%
-194.47 %+373.63%
-41.06 %-64.94%
-117.10 %+87,531.12%
-0.13 %-78.63%
-0.63 %-1,389.43%
0.05 %-124.52%
-0.20 %-19.95%
-0.25 %+97.96%
-0.12 %+169.82%
-0.05 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

STCube Stock analysis

What does STCube do? STCube Inc. generates revenue through its two business segments. The IT segment distributes CCTV lenses and related components, targeting businesses requiring security solutions. The BT segment develops and licenses immunomodulatory anticancer drug therapeutic candidates, selling to pharmaceutical companies and research institutions. Both segments operate under the company's brand, leveraging its IT and biotechnology expertise. The IT segment focuses on closed-circuit television lens distribution, serving commercial and industrial clients seeking reliable security infrastructure. The BT segment's drug development and licensing activities cater to the pharmaceutical industry, providing innovative therapeutic candidates for cancer treatment. These offerings align with STCube's dual expertise in technology and biotechnology. STCube's revenue streams are derived from product distribution in the IT sector and licensing agreements in the biotechnology sector. The company's clients include businesses needing CCTV components and pharmaceutical firms interested in anticancer drug development. This dual approach allows STCube to serve distinct market segments with specialized solutions. STCube is one of the most popular companies on Eulerpool.

Frequently Asked Questions about STCube stock

Net Profit Margin of STCube is -312.14 % in 2025.

Net Profit Margin of STCube changed from -189.74 % to -312.14 %, representing a 64.50% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin STCube since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's STCube with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — STCube

All Key Metrics — STCube